Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar

The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, Dhanya Kizhakayil, Chiara Bonini, Reuben Benjamin, Renier Brentjens, Christian J. Buchholz, Giulia Casorati, Soldano Ferrone, Frederick L. Locke, Francisco Martin, Axel Schambach, Cameron Turtle, Paul Veys, Hans J. van der Vliet, Cristina Maccalli, The EICCI Faculty Group
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2021-01-01
Col·lecció:	Frontiers in Immunology
Matèries:	cancer immunotherapy CAR-T cells TCR engineered lymphocytes CAR-NK cells monoclonal antibody
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.589381/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!